Sobi, an international biopharmaceutical company dedicated to rare diseases, announced today that Kevin Springman has joined the company as the Vice President, Franchise Head of Synagis® (palivizumab) in North America.
Springman has over 22 years of pharmaceutical and biotech experience spanning sales, marketing, market access, strategic project management and patient services. He spent two decades at AstraZeneca, most recently serving as Franchise Head of Infectious Disease. He previously served as a Senior Director of Strategic Products, and prior to that advanced through multiple sales, marketing and other commercial positions. Kevin received his bachelor’s degree from St. Joseph’s University and completed a post-graduate program at Fork Union Military Academy.
“With the completion of Sobi’s acquisition of rights to Synagis in the U.S., Sobi in North America was pleased to welcome the Synagis sales and marketing team, including Kevin as the franchise head, to our North American team. This acquisition nearly tripled the size of our organization, establishing a critical scale to drive sustainable growth in the U.S. Additionally, Kevin’s deep understanding of Synagis specifically and of strategic sales and marketing generally will make him a valuable addition to our leadership team,” said Rami Levin, President of Sobi in North America.
“I have had the privilege of helping deliver Synagis not only to physicians and hospitals but also the patients that need it for several years, and I am grateful to now have the opportunity to help Sobi continue this important work,” said Springman.
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.